ArticleFrontiers in immunology2019
NF-κB/mTOR/MYC Axis Drives PRMT5 Protein Induction After T Cell Activation via Transcriptional and Non-transcriptional Mechanisms.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Sublytic C5b-9 induces S100A8/A9 expression via SMYD4-dependent SOX7-K159 methylation in the glomerular mesangial cells of Thy-1 nephritis rats.Journal of molecular cell biology · 2026Article
- Inhibition of PRMT5 reduces angiogenesis in a corneal neovascularization model by blocking NLRP3-mediated pyroptosis.Clinical epigenetics · 2026Article
- Protein Arginine Methyltransferases in γ-Globin Regulation and Sickle Cell Disease: Emerging Connections to Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Review
- The Acid sphingomyelinase/ceramide System in Idiopathic Inflammatory Myopathies: a Potential Treatment Target.Inflammation · 2026Review
- Taurine corrects lupus CD4Nutrition & metabolism · 2025Article
- Disease Aggravation With Age in an Experimental Model of Multiple Sclerosis: Role of Immunosenescence.Aging cell · 2025Article
- PRMT5 Promotes T follicular helper Cell Differentiation and Germinal Center Responses during Influenza Virus Infection.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- MYC: there is more to it than cancer.Frontiers in cell and developmental biology · 2024Review
- PRMT5 inhibition induces pro-inflammatory macrophage polarization and increased hepatic triglyceride levels without affecting atherosclerosis in mice.Journal of cellular and molecular medicine · 2023Article
- Weighted gene co-expression network analysis revealed T cell differentiation associated with the age-related phenotypes in COVID-19 patients.BMC medical genomics · 2023Article
- PRMT5 critically mediates TMAO-induced inflammatory response in vascular smooth muscle cells.Cell death & disease · 2022Article
- PRMT5 in T Cells Drives Th17 Responses, Mixed Granulocytic Inflammation, and Severe Allergic Airway Inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach.Frontiers in cell and developmental biology · 2022Article
- PRMT5 Promotes Symmetric Dimethylation of RNA Processing Proteins and Modulates Activated T Cell Alternative Splicing and CaImmunoHorizons · 2021Article
- PRMT5: An Emerging Target for Pancreatic Adenocarcinoma.Cancers · 2021Review
- FKBP4 integrates FKBP4/Hsp90/IKK with FKBP4/Hsp70/RelA complex to promote lung adenocarcinoma progression via IKK/NF-κB signaling.Cell death & disease · 2021Article
- Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer.Molecular cancer research : MCR · 2021Review
- PRMT5 Promotes Cyclin E1 and Cell Cycle Progression in CD4 Th1 Cells and Correlates With EAE Severity.Frontiers in immunology · 2021Article
- Protein Arginine Methyltransferase 5 Promotes the Migration of AML Cells by Regulating the Expression of Leukocyte Immunoglobulin-Like Receptor B4.BioMed research international · 2021Article
- Upregulation of MTOR, RPS6KB1, and EIF4EBP1 in the whole blood samples of Iranian patients with multiple sclerosis compared to healthy controls.Metabolic brain disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Lindsay M WebbDivision of Medical Laboratory Science, Wexner Medical Center, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University, Columbus, OH, United States.
Janiret Narvaez MirandaDivision of Medical Laboratory Science, Wexner Medical Center, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University, Columbus, OH, United States.
Stephanie A AmiciDivision of Medical Laboratory Science, Wexner Medical Center, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University, Columbus, OH, United States.
Shouvonik SenguptaDivision of Medical Laboratory Science, Wexner Medical Center, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University, Columbus, OH, United States.
Gregory NagyBiomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, United States.
Mireia Guerau-de-ArellanoDivision of Medical Laboratory Science, Wexner Medical Center, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University, Columbus, OH, United States.
The Ohio State University Wexner Medical Center · USThe Ohio State University · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MEpigenetic modulation of T cell tolerance in Multiple Sclerosis autoimmunityR01AI121405 · NIAID · OHIO STATE UNIVERSITY · PI GUERAU-DE-ARELLANO, MIREIA · 2016 to 2020
$2.2MNovel Epigenetic Modifier Inhibitor Drugs for T cell Modulation in Multiple SclerosisR21AI127354 · NIAID · OHIO STATE UNIVERSITY · PI GUERAU-DE-ARELLANO, MIREIA · 2017 to 2018
$404kNCI NIH HHS P30 CA016058NIAID NIH HHS R01 AI121405NIAID NIH HHS R21 AI127354
Abstract
Multiple sclerosis is an autoimmune disease of the central nervous system (CNS) mediated by CD4
Indexed as
AnimalsCell LineEncephalomyelitis, Autoimmune, ExperimentalLymphocyte ActivationMiceMice, Inbred C57BLMice, TransgenicMultiple SclerosisNF-kappa BProtein-Arginine N-MethyltransferasesProto-Oncogene Proteins c-mycTh1 CellsTh2 CellsTOR Serine-Threonine KinasesTranscription, GeneticmTOR protein, mouseNF-kappa BPrmt5 protein, mouseProtein-Arginine N-MethyltransferasesProto-Oncogene Proteins c-mycTOR Serine-Threonine Kinasesmemorymultiple sclerosisnaivePRMT5signalingT cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.